



PolyNovo Limited
ABN 96 083 866 862
2/320 Lorimer Street
Port Melbourne
VIC Australia 3207
P +61 (0) 3 8681 4050

14 July 2025

ASX Announcement

Special Briefing with Professor Toby Coates

Anyone with an interest in Type 1 diabetes should take note of this briefing today hosted by Bell Potter.

Professor Toby Coates is the Director of Kidney and Pancreatic Islet Transplant Surgery at Royal Adelaide Hospital. He recently used PolyNovo's NovoSorb to aid in the successful transplant of islet cells into a long-term Type 1 diabetic. This is a new market for NovoSorb and demonstrates the flexibility and platform nature of the product.

To join the webcast at **10.30am AEST** today, please refer to dial details below:

<https://bellfg-au.zoom.us/j/85776599295?pwd=liQ8mwPISUqTTLyXRDCviSYBr7bqgr.1#success>

Meeting ID: 857 7659 9295

Passcode: 450195

This announcement has been authorised by PolyNovo Company Secretary, Jan Gielen.

About PolyNovo®

PolyNovo is a disruptive medical technology company, headquartered in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. The Company has treated 70,000+ patients in 46 countries and is investing for growth via new products, indications, and markets. For more information see polynovo.com.

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.